Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension-Reference-Cited by-同舟云学术

Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension

Published:2019-05 Issue: Volume:850 Page:126-134
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Cantoni Silvia,Cavalli Stefano,Pastore Fiorella,Accetta Alessandro,Pala Daniele,Vaccaro Fabio,Cesari Nicola,De Logu Francesco^ORCID,Nassini Romina,Villetti Gino,Facchinetti Fabrizio

Funder

Chiesi Farmaceutici

Publisher

Elsevier BV

Subject

Pharmacology

Reference41 articles.

1. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats;Abe;Circ. Res.,2004

2. Energetic dissection of Gleevec's selectivity towards human tyrosine kinases;Agafonov;Nat. Struct. Mol. Biol.,2014

3. Protein Kinase inhibitor, Fasudil (AT-877): a novel approach to signal transduction therapy;Asano;Cardiovasc. Drug Rev.,1998

4. Translating research into improved patient care in pulmonary arterial hypertension;Bonnet;Am. J. Respir. Crit. Care Med.,2017

5. ASK1 inhibition halts disease progression in preclinical models of pulmonary arterial hypertension;Budas;Am. J. Respir. Crit. Care Med.,2018

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sildenafil improves hemodynamic changes caused by acute pulmonary embolism by inhibiting Rho kinase activity;Journal of International Medical Research;2024-04

2. Pulmonary Hypertension: Unveiling Molecular Mechanisms, Diagnosis, and Therapeutic Targets;Journal of Personalized Medicine;2023-09-28

3. Recent advances in the development of Rho kinase inhibitors (2015–2021);Medicinal Research Reviews;2023-06-02

4. Novel and emerging therapies in pulmonary arterial hypertension;Frontiers in Drug Discovery;2022-12-15

5. Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia;Frontiers in Pharmacology;2022-12-06